Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States and Europe. The company offers Fintepla, a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome. It also develops MT-1621, an investigational therapy for the treatment of a rare genetic disease called thymidine kinase 2 deficiency (TK2d). Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development, and commercialization of novel gene therapies for Dravet Syndrome and other epilepsy disorders. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. The company was incorporated in 2006 and is headquartered in Emeryville, California. Zogenix, Inc. is a subsidiary of UCB BioSciences, Inc.